News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Apr 16, 2026 at 16:45 Big Tech Stable Warm

RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban

There doesn't seem to be new safety or efficacy data, but Kennedy touts them anyway.

Signal weather

Stable

The story has moved beyond the first headline and now acts as a reliable context anchor.

By Beth Mole Original source
RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban

The Food and Drug Administration on Wednesday announced meeting dates for advisors to discuss lifting restrictions on 12 unproven peptides that the agency deemed to pose significant safety risks in 2023. The meetings are scheduled for two days in July, with another in February 2027. The scheduled meetings do not appear to be accompanied by any significant new safety or efficacy data for FDA advisors to discuss. Rather, the FDA is being pushed to ease restrictions on these peptides at the behest of anti-vaccine Health Secretary Robert F. Kennedy Jr., who has described himself as a "big fan" of the unproven drugs. Peptide drugs are simply those made of short chains of amino acids linked by peptide bonds. FDA-approved peptide drugs include insulin for diabetes and GLP-1 drugs for obesity. But online, peptides typically refer to unproven drugs, often given by injection, that are peddled without evidence as treating various conditions, reversing aging, and improving appearance. This category has seen a boom in popularity among wellness influencers, including Kennedy and many of his allies. Read full article Comments

Stay on the signal

Follow RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

This story is still moving and pulling follow-up coverage.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Ars Technica, Efficacy Data, and FDA, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

Jun 8, 2026 at 17:20 Ars Technica

Man jailed for a month despite Flock showing he was 5 miles from crime scene

Cop seemingly ignored Flock camera timestamp to justify arrests.

Jun 8, 2026 at 16:56 Ars Technica

F1 in Monaco: Finally, the cars were flat-out in qualifying

The cars are too big to race well, but the competition for pole position is thrilling.

Jun 8, 2026 at 16:05 Ars Technica

A Falcon 9 booster turns 5 years old—and just set a remarkable reuse record

We take the Falcon 9 rocket for granted. But we probably shouldn't.

Jun 8, 2026 at 14:02 Ars Technica

Michigan politicians want to ban Chinese-badged cars from even visiting the US

The latest bill would ban day trips from Canada or Mexico in Chinese cars.

Jun 8, 2026 at 11:00 Ars Technica

The weather and climate science AI revolution isn’t revolutionary

Machine learning has its limits—how is it being used?

Apr 16, 2026 at 16:45 Ars Technica

RFK Jr. forces FDA to reconsider 12 unproven peptides after 2023 ban

There doesn't seem to be new safety or efficacy data, but Kennedy touts them anyway.

How reliable this looks

Signal and trust for Ars Technica

This source works at a steady pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

1

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page